Alkem reports posts Q1 FY26 net profit 22% higher at 664.3 Cr
Alkem’s domestic business grew 9.7 per cent versus the Indian pharmaceutical market growth of 8.5 per cent
Alkem’s domestic business grew 9.7 per cent versus the Indian pharmaceutical market growth of 8.5 per cent
The company’s acquisition of a 51 per cent stake in Saarathi Healthcare earlier this financial year boosted growth
During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
SMS Pharmaceuticals has reported total income of Rs. 196.64 crores during the period ended June 30, 2025
Emcure Pharmaceuticals has reported total income of Rs. 2,104.23 crores during the period ended June 30, 2025
Consolidated revenue from operations in the quarter was marginally down at Rs 738 crore a
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
Subscribe To Our Newsletter & Stay Updated